Comments
Loading...

Sage Therapeutics Analyst Ratings

SAGENASDAQ
Logo brought to you by Benzinga Data
Consensus Rating1
Neutral
Highest Price Target1
$49.00
Lowest Price Target1
$4.00
Consensus Price Target1
$13.33

Sage Therapeutics Analyst Ratings and Price Targets | NASDAQ:SAGE | Benzinga

Sage Therapeutics Inc has a consensus price target of $13.33 based on the ratings of 23 analysts. The high is $49 issued by Citigroup on May 3, 2023. The low is $4 issued by RBC Capital on November 21, 2024. The 3 most-recent analyst ratings were released by Scotiabank, Wedbush, and Canaccord Genuity on February 12, 2025, respectively. With an average price target of $8.67 between Scotiabank, Wedbush, and Canaccord Genuity, there's an implied 1.90% upside for Sage Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
5
2
Oct 24
1
Nov 24
0
0
0
0
Dec 24
1
Jan
2
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.4
Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Scotiabank
Wedbush
Canaccord Genuity
HC Wainwright & Co.
Piper Sandler

1calculated from analyst ratings

Analyst Ratings for Sage Therapeutics

Buy NowGet Alert
02/12/2025Buy Now41.09%Scotiabank
George Farmer48%
$14 → $12MaintainsSector OutperformGet Alert
02/12/2025Buy Now-29.45%Wedbush
Laura Chico48%
$6 → $6ReiteratesNeutral → NeutralGet Alert
02/12/2025Buy Now-5.94%Canaccord Genuity
Sumant Kulkarni45%
$9 → $8MaintainsHoldGet Alert
02/12/2025Buy Now41.09%HC Wainwright & Co.
Douglas Tsao53%
$14 → $12ReiteratesNeutral → NeutralGet Alert
02/12/2025Buy NowNeedham
Ami Fadia62%
ReiteratesHold → HoldGet Alert
01/02/2025Buy Now5.82%Piper Sandler
David Amsellem69%
$26 → $9MaintainsOverweightGet Alert
12/16/2024Buy Now-29.45%Stifel
Paul Matteis43%
$10 → $6MaintainsHoldGet Alert
11/21/2024Buy Now5.82%TD Cowen
Ritu Baral36%
$10 → $9MaintainsHoldGet Alert
11/21/2024Buy Now-52.97%RBC Capital
Brian Abrahams52%
$4 → $4UpgradeUnderperform → Sector PerformGet Alert
11/20/2024Buy Now64.61%HC Wainwright & Co.
Douglas Tsao53%
$14 → $14ReiteratesNeutral → NeutralGet Alert
11/20/2024Buy NowNeedham
Ami Fadia62%
Reiterates → HoldGet Alert
10/30/2024Buy Now64.61%Scotiabank
George Farmer48%
$17 → $14MaintainsSector OutperformGet Alert
10/30/2024Buy Now205.7%Piper Sandler
Yasmeen Rahimi61%
$52 → $26ReiteratesOverweight → OverweightGet Alert
10/30/2024Buy Now-5.94%Oppenheimer
Jay Olson62%
$9 → $8MaintainsPerformGet Alert
10/30/2024Buy Now-5.94%Truist Securities
Joon Lee78%
$13 → $8MaintainsHoldGet Alert
10/30/2024Buy Now64.61%HC Wainwright & Co.
Douglas Tsao53%
$25 → $14MaintainsNeutralGet Alert
10/30/2024Buy NowNeedham
Ami Fadia62%
Reiterates → HoldGet Alert
10/17/2024Buy NowNeedham
Ami Fadia62%
Reiterates → HoldGet Alert
10/10/2024Buy NowRaymond James
Danielle Brill43%
Reinstates → Market PerformGet Alert
10/09/2024Buy Now-29.45%B of A Securities
Tazeen Ahmad56%
$11 → $6MaintainsUnderperformGet Alert
10/09/2024Buy Now-5.94%Wedbush
Laura Chico48%
$9 → $8MaintainsNeutralGet Alert
10/09/2024Buy Now5.82%Baird
Joel Beatty69%
$13 → $9MaintainsNeutralGet Alert
10/09/2024Buy Now193.94%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesNeutral → NeutralGet Alert
10/08/2024Buy NowNeedham
Ami Fadia62%
Reiterates → HoldGet Alert
10/04/2024Buy Now-52.97%RBC Capital
Brian Abrahams52%
$10 → $4DowngradeSector Perform → UnderperformGet Alert
08/14/2024Buy Now52.85%Truist Securities
Joon Lee78%
$18 → $13MaintainsHoldGet Alert
08/06/2024Buy Now17.58%JP Morgan
Anupam Rama60%
$12 → $10MaintainsNeutralGet Alert
08/02/2024Buy Now193.94%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesNeutral → NeutralGet Alert
08/01/2024Buy Now511.41%Piper Sandler
Yasmeen Rahimi61%
$70 → $52MaintainsOverweightGet Alert
08/01/2024Buy NowNeedham
Ami Fadia62%
Reiterates → HoldGet Alert
07/30/2024Buy Now17.58%TD Cowen
Ritu Baral36%
$16 → $10DowngradeBuy → HoldGet Alert
07/26/2024Buy Now29.34%Goldman Sachs
Salveen Richter53%
$19 → $11MaintainsNeutralGet Alert
07/25/2024Buy Now99.88%Scotiabank
George Farmer48%
$19 → $17MaintainsSector OutperformGet Alert
07/25/2024Buy Now41.09%JP Morgan
Anupam Rama60%
$18 → $12DowngradeOverweight → NeutralGet Alert
07/25/2024Buy Now52.85%Baird
Joel Beatty69%
$15 → $13MaintainsNeutralGet Alert
07/25/2024Buy Now193.94%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesNeutral → NeutralGet Alert
07/24/2024Buy NowNeedham
Ami Fadia62%
Reiterates → HoldGet Alert
07/19/2024Buy Now88.12%Mizuho
Uy Ear63%
$18 → $16MaintainsNeutralGet Alert
07/12/2024Buy Now111.64%JP Morgan
Anupam Rama60%
$23 → $18MaintainsOverweightGet Alert
07/02/2024Buy Now193.94%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesNeutral → NeutralGet Alert
06/28/2024Buy NowNeedham
Ami Fadia62%
Reiterates → HoldGet Alert
06/20/2024Buy Now170.43%JP Morgan
Anupam Rama60%
$28 → $23MaintainsOverweightGet Alert
06/12/2024Buy Now193.94%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesNeutral → NeutralGet Alert
06/11/2024Buy NowNeedham
Ami Fadia62%
Reiterates → HoldGet Alert
06/11/2024Buy Now76.37%Baird
Joel Beatty69%
$15 → $15MaintainsNeutralGet Alert
05/29/2024Buy Now-5.94%Citigroup
David Hoang42%
→ $8Initiates → SellGet Alert
05/29/2024Buy Now76.37%Baird
Joel Beatty69%
→ $15Initiates → NeutralGet Alert
05/01/2024Buy Now229.22%JP Morgan
Anupam Rama60%
$29 → $28MaintainsOverweightGet Alert
04/26/2024Buy Now193.94%HC Wainwright & Co.
Douglas Tsao53%
$28 → $25MaintainsNeutralGet Alert
04/26/2024Buy Now123.4%Goldman Sachs
Salveen Richter53%
$28 → $19MaintainsNeutralGet Alert
04/26/2024Buy Now76.37%RBC Capital
Brian Abrahams52%
$26 → $15MaintainsSector PerformGet Alert
04/26/2024Buy Now111.64%Truist Securities
Joon Lee78%
$22 → $18MaintainsHoldGet Alert
04/26/2024Buy Now111.64%Mizuho
Uy Ear63%
$20 → $18MaintainsNeutralGet Alert
04/26/2024Buy Now99.88%Canaccord Genuity
Sumant Kulkarni45%
$21 → $17MaintainsHoldGet Alert
04/26/2024Buy NowNeedham
Ami Fadia62%
Reiterates → HoldGet Alert
04/25/2024Buy NowNeedham
Ami Fadia62%
Reiterates → HoldGet Alert
04/18/2024Buy Now123.4%Scotiabank
George Farmer48%
$34 → $19MaintainsSector OutperformGet Alert
04/18/2024Buy Now99.88%Oppenheimer
Jay Olson62%
$25 → $17MaintainsPerformGet Alert
04/18/2024Buy Now88.12%TD Cowen
Ritu Baral36%
$30 → $16MaintainsBuyGet Alert
04/18/2024Buy NowNeedham
Ami Fadia62%
Reiterates → HoldGet Alert
04/17/2024Buy Now229.22%HC Wainwright & Co.
Douglas Tsao53%
$28 → $28ReiteratesNeutral → NeutralGet Alert
04/17/2024Buy Now182.19%Wedbush
Laura Chico48%
$24 → $24ReiteratesNeutral → NeutralGet Alert
04/17/2024Buy Now64.61%B of A Securities
Tazeen Ahmad56%
$24 → $14DowngradeNeutral → UnderperformGet Alert
03/26/2024Buy Now240.98%JP Morgan
Anupam Rama60%
$24 → $29MaintainsOverweightGet Alert
03/11/2024Buy Now205.7%RBC Capital
Brian Abrahams52%
$26 → $26ReiteratesSector Perform → Sector PerformGet Alert
02/28/2024Buy Now158.67%Morgan Stanley
Vikram Purohit38%
$20 → $22MaintainsEqual-WeightGet Alert
02/15/2024Buy Now229.22%HC Wainwright & Co.
Douglas Tsao53%
$25 → $28MaintainsNeutralGet Alert
02/15/2024Buy Now205.7%RBC Capital
Brian Abrahams52%
$21 → $26MaintainsSector PerformGet Alert
12/18/2023Buy Now135.16%Stifel
Paul Matteis43%
$22 → $20MaintainsHoldGet Alert
12/12/2023Buy Now146.91%Deutsche Bank
Neena Bitritto-Garg59%
→ $21Initiates → HoldGet Alert
11/08/2023Buy Now146.91%RBC Capital
Brian Abrahams52%
$22 → $21MaintainsSector PerformGet Alert
11/08/2023Buy Now158.67%Wedbush
Laura Chico48%
$21 → $22MaintainsNeutralGet Alert
10/13/2023Buy Now193.94%Goldman Sachs
Salveen Richter53%
$22 → $25MaintainsNeutralGet Alert
09/08/2023Buy Now182.19%B of A Securities
Tazeen Ahmad56%
$25 → $24MaintainsNeutralGet Alert
09/07/2023Buy Now135.16%Mizuho
Vamil Divan76%
$19 → $20MaintainsNeutralGet Alert
09/07/2023Buy Now158.67%RBC Capital
Brian Abrahams52%
$25 → $22MaintainsSector PerformGet Alert
08/09/2023Buy Now158.67%Goldman Sachs
Salveen Richter53%
$75 → $22MaintainsNeutralGet Alert
08/09/2023Buy Now135.16%Morgan Stanley
Vikram Purohit38%
$49 → $20MaintainsEqual-WeightGet Alert
08/08/2023Buy Now229.22%TD Cowen
Ritu Baral36%
$105 → $28MaintainsOutperformGet Alert
08/08/2023Buy Now135.16%Oppenheimer
Jay Olson62%
$24 → $20MaintainsPerformGet Alert
08/08/2023Buy Now193.94%RBC Capital
Brian Abrahams52%
→ $25ReiteratesSector Perform → Sector PerformGet Alert
08/08/2023Buy Now135.16%Truist Securities
Joon Lee78%
$40 → $20MaintainsHoldGet Alert
08/08/2023Buy Now123.4%Mizuho
Vamil Divan76%
$45 → $19MaintainsNeutralGet Alert
08/08/2023Buy Now158.67%Goldman Sachs
Salveen Richter53%
→ $22DowngradeBuy → NeutralGet Alert
08/08/2023Buy Now146.91%Canaccord Genuity
Sumant Kulkarni45%
$64 → $21DowngradeBuy → HoldGet Alert
08/08/2023Buy NowNeedham
Ami Fadia62%
DowngradeBuy → HoldGet Alert
08/08/2023Buy Now217.46%HC Wainwright & Co.
Douglas Tsao53%
$50 → $27MaintainsNeutralGet Alert
08/07/2023Buy Now158.67%Stifel
Paul Matteis43%
$60 → $22DowngradeBuy → HoldGet Alert
08/07/2023Buy Now158.67%Wedbush
Laura Chico48%
→ $22DowngradeOutperform → NeutralGet Alert
08/07/2023Buy Now487.89%HC Wainwright & Co.
Douglas Tsao53%
→ $50ReiteratesNeutral → NeutralGet Alert
08/07/2023Buy Now193.94%RBC Capital
Brian Abrahams52%
$71 → $25DowngradeOutperform → Sector PerformGet Alert
08/07/2023Buy NowOppenheimer
Jay Olson62%
DowngradeOutperform → PerformGet Alert
08/07/2023Buy Now723.05%Needham
Ami Fadia62%
→ $70ReiteratesBuy → BuyGet Alert
08/03/2023Buy Now476.13%Morgan Stanley
Vikram Purohit38%
$49 → $49MaintainsEqual-WeightGet Alert
07/27/2023Buy Now617.23%Scotiabank
George Farmer48%
→ $61Initiates → Sector OutperformGet Alert
05/23/2023Buy Now617.23%B of A Securities
Tazeen Ahmad56%
$56 → $61MaintainsBuyGet Alert
05/23/2023Buy Now487.89%HC Wainwright & Co.
Douglas Tsao53%
→ $50ReiteratesNeutral → NeutralGet Alert
05/09/2023Buy Now476.13%Morgan Stanley
Vikram Purohit38%
$50 → $49MaintainsEqual-WeightGet Alert
05/03/2023Buy Now558.44%B of A Securities
Tazeen Ahmad56%
$55 → $56MaintainsBuyGet Alert
05/03/2023Buy Now476.13%Citigroup
Neena Bitritto-Garg59%
$46 → $49MaintainsNeutralGet Alert

FAQ

Q

What is the target price for Sage Therapeutics (SAGE) stock?

A

The latest price target for Sage Therapeutics (NASDAQ:SAGE) was reported by Scotiabank on February 12, 2025. The analyst firm set a price target for $12.00 expecting SAGE to rise to within 12 months (a possible 41.09% upside). 64 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Sage Therapeutics (SAGE)?

A

The latest analyst rating for Sage Therapeutics (NASDAQ:SAGE) was provided by Scotiabank, and Sage Therapeutics maintained their sector outperform rating.

Q

When was the last upgrade for Sage Therapeutics (SAGE)?

A

The last upgrade for Sage Therapeutics Inc happened on November 21, 2024 when RBC Capital raised their price target to $4. RBC Capital previously had an underperform for Sage Therapeutics Inc.

Q

When was the last downgrade for Sage Therapeutics (SAGE)?

A

The last downgrade for Sage Therapeutics Inc happened on October 4, 2024 when RBC Capital changed their price target from $10 to $4 for Sage Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Sage Therapeutics (SAGE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sage Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sage Therapeutics was filed on February 12, 2025 so you should expect the next rating to be made available sometime around February 12, 2026.

Q

Is the Analyst Rating Sage Therapeutics (SAGE) correct?

A

While ratings are subjective and will change, the latest Sage Therapeutics (SAGE) rating was a maintained with a price target of $14.00 to $12.00. The current price Sage Therapeutics (SAGE) is trading at is $8.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch